Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Targeted regulation of adipose tissue macrophages from an immunometabolic perspective: a novel therapeutic approach for obesity-related metabolic disorders

Jia C., Wu E., Zhu C., Guan X., Cheng Y., Zhao F.

Narrative Review on Type 2 Diabetes, Chronic Inflammation, published in Front Immunol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Immunol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42051485
PMCID
PMC13112897
DOI
10.3389/fimmu.2026.1803488
Citations
1

Abstract (original English)

The global prevalence of obesity and its associated metabolic syndromes, characterized by chronic inflammation and metabolic disorders, poses a major health threat worldwide. This makes it urgent to gain a deeper understanding of its pathogenesis and to develop new therapeutic strategies. Adipose tissue macrophages (ATMs), as central regulators of the adipose tissue immune microenvironment, exhibit functional polarization closely linked to obesity-associated chronic low-grade inflammation and insulin resistance. This review systematically elucidates the mechanisms of metabolic reprogramming in adipose tissue microenvironment under obesity, focusing on how profound alterations in their glucose, lipid, and amino acid metabolic networks drive their shift toward a pro-inflammatory phenotype. Building on this, we review the mechanisms of action and latest research advances in emerging therapeutic strategies, including mitochondrial-targeted interventions, extracellular vesicle (EV)-mediated molecular delivery, probiotic/prebiotic modulation, probiotic extracellular vesicles, and nanotechnology-enabled precision interventions. Finally, this review outlines the challenges and future directions for treating obesity-related diseases by precisely regulating the EV-ATMs metabolic axis.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueMacrophagesAnimalsHumansMetabolic DiseasesObesityExtracellular VesiclesMetabolic Reprogramming

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research